www.hivandhepatitis.com

IAS 2013: Second-line Therapy in Resource-limited Settings [VIDEO]

A second-line regimen of a protease inhibitor plus either 2 NRTIs or raltegravir (Isentress) led to good outcomes for people with HIV in Africa after initial regimen failure, according to a study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

In contrast, Nicholas Paton reported, the EARNEST (Europe-Africa Research Network for Evaluation of Second-line Therapy)study found that protease inhibitor monotherapy following raltegravir induction did not work as well.

Patongave a summary of the EARNEST results at a press conference prior to his late-breaker presentation.

[Nicholas Paton speaks at IAS 2013 press conference, Kuala Lumpur, July 1, 2013]

See also: IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries

7/8/13

Reference

N Paton, C Kityo, A Hoppe, et al. A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, June 30-July 3, 2013. Abstract WELBB02.